IDEAYA Biosciences will participate in major investor events on November 16-17, 2026, including the UBS Global Biopharma Conference and Jefferies Global Healthcare Conference. The company will present updates on its cancer drug candidates, including IDE892, a promising PRMT5 inhibitor, and discuss clinical progress in targeting MTAP/CDKN2A and RAS-driven cancers. These events will feature presentations from top executives and scientific experts, highlighting IDEAYA's pipeline and upcoming milestones. Live webcasts will be available for investors to follow the developments.
IDEAYA Biosciences is set to participate in investor relations events in November 2026. For readers following the health sector, here is Pluang's market snapshot as of Nov 04, 2026 16:01 WIB: Out of 150 priced US health stocks, 74 rose and 65 fell. Notable movers include DYN at USD 16.43 with a -8.98% change and a typical hold time of 10 days, SYRE at USD 90.62 down by -8.71% with a 5-day hold, and ABEO at USD 4.55 up by 7.06% with 100% buy order activity and a 28-day hold time.
KE Holdings Inc., a major online and offline housing platform in China, will announce its unaudited financial results for the third quarter of 2026 on November 16 before the U.S. market opens. The company will host an earnings conference call at 7:00...
JD.com announced it will publish its unaudited financial results for the third quarter of 2026 on November 17, before the U.S. market opens. The company's management will hold a conference call the same day to discuss the results, providing investors...
Dimensional Fund Advisors Ltd. filed a Form 8.3 disclosure revealing it holds a 1.27% stake in Prologis Inc as of November 3, 2026. This disclosure is part of regulatory requirements under the Takeover Code for investors holding 1% or more in relevan...
Dimensional Fund Advisors Ltd. has disclosed an interest in 1,516,595 ordinary shares of DCC Energy plc, representing 1.78% of the company's shares as of November 3, 2026. The disclosure follows regulatory requirements under the Irish Takeover Panel ...
Sampo Oyj has canceled 37,827,020 of its own A-shares as per the board's decision, with the cancellation registered today. These shares were acquired through a buyback program announced on May 6, 2026, and repurchased between May 7 and September 24, ...
